| Authors: |
Richardson PG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Harrison SJ; Peter MacCallum Cancer Centre & Royal Melbourne Hospital Melbourne, Sir Peter MacCallum Department of Oncology, University of Melbourne Parkville, Victoria, 3010, Australia., Bringhen S; Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino 10126, Italy., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo 0188, Norway.; KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo 0315, Norway., Yong K; Department of Haematology, University College London Hospitals, London WC1N 3BG, UK., Campana F; Sanofi R&D, Cambridge, MA 02142, USA.; Currently, Takeda Pharmaceuticals, Cambridge, MA 02142, USA., Le-Guennec S; Sanofi R&D, Vitry-sur-Seine 94400, France., Macé S; Sanofi R&D, Vitry-sur-Seine 94400, France., Dimopoulos MA; Department of Clinical Therapeutics, National & Kapodistrian University of Athens, Athens 157 72, Greece. |
